Diabetes Management

1. An Innovation in
Diabetes Management

2. CHERESO, incorporated in 2003 is a firm dedicated
to the principles of tradition, innovation and
research.
CHERESO is a manufacture, exporter and supplier
of APIs, nutraceuticals and health supplements.
CHERESO is 100% EOU and is 9001:2015, ISO
22000:2005, Kosher, Halal, ZED- Gold WHO GMP
and NSF-US GMP certified.
CHERESO owns popular and famous brands;
Fenfuro, Furocyst and Chemforce, Prosman,
GCB70 & Grecobe which have carved their way in
the market of diabetes, women’s health, men’s
health, antioxidants & weight loss.
About Us

3. A proprietary product derived from Fenugreek seeds
(Trigonella Foenum Graecum) by an innovative
process. It is a group of furostanolic saponins that help
to maintain healthy blood glucose levels. FENFURO
contains a rich variety of saponins and flavonoids. All
of these substances are known to play valuable role in
maintaining a stable glucose levels.
Each capsule contains
Fenugreek Seeds Extract 500 mg

4. FEATURES OF
100% natural and innovative
Extracted naturally from Fenugreek seeds
It is a single herb extract without additives and excipients
Suitable to maintain blood glucose level
Supported by 7 international patents
Clinically Evaluated on 462 patients
No known side effects
Halal and Kosher certified
Mitigates the risk of unhealthy blood glucose level
Easily digested and readily absorbed
30 convenient capsules to allow you to take anywhere with you

5. S. No Country Patent No. Title
1 US
US 8,754, 205
B2
An Extract obtained by a commercialy viable process for
the extraction of Furostanolic Saponins from Fenugreek
Seeds in which one of the compound in the extract is
Protodioscin.
2 US
US 8,217,165
B2
Process for the extraction of Furostanolic Saponins from
Fenugreek Seeds
3 CHINA
CN102448479
B
A novel anti-diabetic furostanolic saponin rich (FSR)
fraction from Fenugreek Seeds
4 EUROPE
EP2285821
B1
A novel process for extraction of Furostanlic Saponins
from Fenugreek Seeds
5 EUROPE 2437763
A novel antidiabetic Furostanolic saponin-rich fraction
from Fenugreek seeds
6 AFRICA AP 3077
A novel Anti-diabetic Furostanolic-Sapponin-Rich (FRS)
Fraction from Fenugreek Seeds
7 INDIA 285647
A Novel Anti-diabetic furostanolic-saponin-rich (FSR)
Fraction from Fenugreek seeds.
Supported by 7 international patents

6. MODE OF ACTION OF
Fenfuro is the first dual action insulin sensitizer and exhibits hypocholestremic
activity. In presence of high fiber Furostanolic saponin cells are more sensitive to
insulin.
An increase in number of insulin receptor sites occurs which are responsive to
insulin to stimulate the cells ability to burn glucose (i.e. newer insulin receptors with
definite insulin sensitizing activity due to specific effects on the islets of langerhans
in the Pancreas)
High fiber Furostanolic saponins delays the rate of gastric emptying and slow
carbohydrate absorption & thereby reducing insulin requirements. THREBY BRINGS
EUGLYCEMIC EFFECTS
Furostanolic saponins also increase peripheral utilization of insulin & THEREBY
BRINGS DOWN THE HYPERINSULLINAMEA the root cause of DIABETIC
COMPLICATIONS
High fiber Furostanolic saponins increases viscosity of the digesta thereby inhibiting
cholesterol absorption from small intestine and also the inhibition of bile acid re-
absorption from the terminal ileum. Thus there is decrease in VLDL, LDL &
Triglycerides level where as no effects on HDL.
F

7. CLINICAL Studies

8. CLINICAL EVALUATION OF
Study 1 carried on 154 subjects
Efficacy conclusion
• 100% of the patients reported decrease in HbA1c levels in the Fenfuro-treated group.
• 83% of the patients reported decrease in fasting sugar levels in Fenfuro treated group.
• 89% of the patients reported decrease in PP sugar levels in Fenfuro treated group.
• 48.8% of the patients reported reduced dosage of anti diabetic therapy in Fenfuro
treated group.

9. CLINICAL EVALUATION OF
Study 2 carried on 107 subjects
Efficacy conclusion
• Decrease in fasting glucose levels was observed in 95.2% of the study
population with FENFURO where as whereas these levels increased in on-going
anti-diabetic therapy-treated patients.
• With FENFURO, 88.10% of study population shown decrease in PP glucose
levels as compared to the on-going anti-diabetic therapy-treated population.
• HbA1c levels decreased significantly in the study population on completion of
the treatment.

10. CLINICAL EVALUATION OF
Safety conclusion (Both Studies)
• No significant change in serum SGOT, SGPT & ALP activities was observed,
indicating investigational product (Fenfuro-fenugreek seed extract) was safe
for liver functioning.
• No significant change in blood urea nitrogen and creatinine levels was
observed indicating investigational product (Fenfuro-fenugreek seed extract)
was safe for kidney functioning.
• No significant change in hematological parameters was observed.

11. CLINICAL EVALUATION OF
Study 3 carried on 200 subjects from one of
the most prestigious institutes of India is
under compilation.

12. Publications in INTERNATIONAL journals

20. Presentations
in
Conferences

21. 6th World Congress of Diabetes India, 2015

27. How do we make

28. www.fenfuro.com

29. Thank you!